Editas Medicine (EDIT)
(Delayed Data from NSDQ)
$3.19 USD
+0.23 (7.77%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.19 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.19 USD
+0.23 (7.77%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.19 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Zacks News
Editas Medicine (EDIT) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101
by Zacks Equity Research
Editas (EDIT) focuses on the development of its lead candidate, EDIT-101, for treating LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a woe.
Glaxo Inks Genome Research Deal With University of California
by Zacks Equity Research
Glaxo (GSK) signs a five-year collaboration contract with the University of California to build a new laboratory for developing new medicines with the aid of CRISPR technologies.
CRISPR Therapeutics Up on Collaboration Expansion by Vertex
by Zacks Equity Research
CRISPR Therapeutics (CRSP) is set to receive $175 million in upfront payment from Vertex following the expansion of the collaboration agreement for gene editing program to include new disease areas.
Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study
by Zacks Equity Research
Adverum's (ADVM) stock gains as the FDA lifts the clinical hold on the second cohort of an initial stage study on lead candidate.
Spectrum Pharma (SPPI) Q1 Earnings Lag Estimates, Revenues Nil
by Zacks Equity Research
Spectrum Pharma (SPPI) misses bottom-line estimates in the first quarter. The company completes sale of its marketed portfolio in March.
IVERIC bio's (ISEE) Q1 Loss Narrows, Gene Therapy in Focus
by Zacks Equity Research
IVERIC bio (ISEE) first-quarter earnings beat estimates. The company is focusing on developing gene therapies for treating inherited retinal diseases.
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Editas (EDIT) delivered earnings and revenue surprises of -5.26% and -73.30%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Geron's (GERN) Q1 Earnings Beat, Revenues Miss, Stock Up
by Zacks Equity Research
Geron (GERN) posts narrower-than-expected loss in first-quarter 2019 but misses on revenues. Operating expenses increase on a year-over-year basis.
ImmunoGen (IMGN) Misses on Earnings & Revenues in Q1
by Zacks Equity Research
ImmunoGen (IMGN) reports wider-than-expected loss in Q1 and misses revenue estimates.
Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (EDIT) Outperforming Other Medical Stocks This Year?
Is a Beat in Store for Editas (EDIT) This Earnings Season?
by Zacks Equity Research
On Editas' (EDIT) first-quarter earnings call, investor focus will be on the company's progress with its most advanced pipeline candidate, EDIT-101.
Editas Medicine (EDIT) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Editas (EDIT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vertex, CRISPR's Gene Editing Drug Gets FDA's Fast Track Tag
by Zacks Equity Research
FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for a second indication - transfusion-dependent beta thalassemia.
Editas (EDIT) Inks Cross Licensing Agreement with BlueRock
by Zacks Equity Research
Editas (EDIT) inks a research and cross licensing agreement with BlueRock Therapeutics, LP.
The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure
Editas (EDIT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Focus of Editas' (EDIT) fourth-quarter conference call is likely to be on its pipeline.
CRISPR Therapeutics Up as Dosing Starts in Thalassemia Study
by Zacks Equity Research
CRISPR Therapeutics (CRSP) and partner Vertex start dosing of beta thalassemia patients in an early-stage study evaluating gene editing therapy, CTX001. Initiates enrollment in sickle cell disease study.
5 Gene Therapy Stocks to Enrich Your Portfolio
by Tirthankar Chakraborty
Gene therapy stocks have not only soared on Roche-Spark deal news but are also poised to make the most of the next gene revolution.
Editas Medicine (EDIT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Editas Medicine (EDIT) closed the most recent trading day at $19.86, moving -0.45% from the previous trading session.
Editas Medicine (EDIT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Editas Medicine (EDIT) closed at $19.75, marking a +1.65% move from the previous day.
Editas Medicine (EDIT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Editas Medicine (EDIT) closed at $21.60, marking a -0.6% move from the previous day.
Editas Medicine (EDIT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Editas Medicine (EDIT) closed at $21.46, marking a +0.61% move from the previous day.
Editas Medicine (EDIT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Editas Medicine (EDIT) closed at $26.03 in the latest trading session, marking a -0.69% move from the prior day.
Editas Medicine (EDIT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Editas Medicine (EDIT) closed at $26.20 in the latest trading session, marking a -0.8% move from the prior day.